Qiagen and CytoPathfinder Combines Technologies in RNAi Screening
News May 24, 2006
Qiagen and CytoPathfinder have announced the formation of a strategic partnership between the two companies to combine their technologies in developing advanced tools for high-throughput RNAi screening.
CytoPathfinder has developed a Transfection Microarray technology (TMA) which allows high-throughput siRNA screening on a microarray chip.
Both companies have agreed to combine product knowledge and technology platforms to develop new-generation tools for high-throughput RNAi screening.
These developments have made high-throughput RNAi accessible to both pharmaceutical companies and academic researchers.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.